Maxime Verhoeven

139 Cost-effectiveness of treat-to-target strategies over 5 years Figure 2 Cost effectiveness planes for the TCZ-based initiation treatment strategy groups versus the MTX initiation strategy group over 5 years, using the societal per- spective (human capital approach). TCZ+MTX= initiation of tocilizumab + methotrexate strategy group; TCZ= initiation of tocilizumab + placebo- methotrexate strategy group; MTX= initiation of methotrexate + placebo-tocilizumab strategy group. Example: TCZ dominated (i.e., more QALYs and less costs) in 8% of all bootstrap samples (8% ‘chance’ that the intervention is cost-effective) compared to MTX. 7